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Cardiac troponin T concentrations before, during, and after
CABG.
(A) = patients without perioperative myocardial infarction (mean and
SD) (B) and (C) = intraoperative myocardial infarction (patient C died
from cardiogenic shock).
concentrations before bypass (126 [0-67] vs 0-24 [0-08] pg/l;
p<005). In 2 patients with intraoperative myocardial infarction
troponin T concentrations were much increased (figure). 1 died
from cardiogenic shock on day 3 (C, see figure). Two other patients
who did not meet criteria for myocardial infarction showed
moderately increased troponin T concentrations (5-9 and 3-5 &micro;g/l at
peak). Only 1 of these patients had borderline CK-MB activities
after reperfusion, but none had new ECG abnormalities after
CABG.
We conclude that cardiac troponin T reliably identifies
perioperative myocardial infarction during CABG. Concentrations
below 2-5 lig/l rule out clinically relevant myocardial injury. The
significant increase in cardiac troponin T after reperfusion in
patients with uncomplicated outcome probably reflects myocardial
cell damage from ischaemia during cardioplegia. Whether the peak
concentrations of 5-9 and 3-5 ug/l in 2 patients not classified as
having myocardial infarction reflect microinfarcts missed by ECG
and CK-MB activity remains to be elucidated.
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Breast milk and necrotising enterocolitis
SIR,&mdash;Dr Lucas and Dr Coles’ report (Dec 22, p 1519) is timely
and gave much needed information about the role of breast milk in
the prevention ofnecrotising enterocolitis (NEC). They also point
out that breast milk is a scarce resource in neonatal units. The other
feature of their results is that the main benefit of breast milk is seen
in the more mature infants. Analysis of their table v shows that, for
both total cases and confirmed cases, breast milk supplements
produce no statistically significant advantage over formula in infants
from 25 to 30 weeks’ gestation and only a modest improvement in
the risk ratio but highly significant and clinically increasing benefits
in more mature infants. This pattern of response has two important
corollaries.
The first is that difficulties of formula feeding are unlikely to lie in
the composition of the major nutrients-for example, the caseine/
whey ratio. If this were the cause of a higher incidence of NEC in
premature infants fed such formula, then the effect should be most
obvious in the smallest infants whose intestinal mucosa is least
mature. Alternatively breast milk might contain a factor that
stimulates a protective response in the intestine of more mature
infants, but not in the very premature infant.
The second corollary is in the selection of infants to receive breast
milk as a protection against NEC. The limited supply of breast milk
should be used where it can do the most good. The table is derived
from Lucas and Cole’s table v, and shows, for all cases of NEC, the
benefit of breast milk by gestational age, expressed as reduction of
incidence of NEC and the number of lives saved.
EFFECT OF BREAST MILK SUPPLEMENTS ON INCIDENCE OF
CLINICAL NEC AND CONSEQUENT DEATH
*Per 1000 infants fed.
tin calculation of deaths prevented, allowance is made for deaths from other causes.
The reduction in incidence of NEC and in resultant mortality
varies with the maturity of the infants. The number of lives saved
rises steadily with gestational age at birth. If breast milk is a limiting
resource then it should be given by choice to more mature infants
who are more likely to benefit. However, there are many such
infants and some selection is necessary, so the use of banked breast
milk supplements should be given first, in the absence of milk from
the mother, to those infants who need enteral feeding.
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SIR,&mdash;Necrotising enterocolitis (NEC) remains a matter of great
concern, and Dr Lucas and Dr Cole show that, with a reduced
intake of breast milk, the incidence of NEC could increase. Human
milk banks do not exist in the Netherlands, and although breast
feeding is supported in our hospital few mothers of very-low-
birthweight (VLBW) infants supply breast milk for their babies.
Psychological stress and the fact that these mothers are recovering
from pregnancy disorders such as pre-eclampsia contribute to this.
Nevertheless, the incidence of NEC in our neonatal intensive care
unit has been very low over the past 7 years.’
Last year 149 VLBW infants were admitted (birthweight 1100
[SD 240] g, gestational age at birth 293 [26] weeks) and
18 2% died. 4 showed grade 1 NEC2 and 2 grade 2; 1 of these 6
infants died at age 3 days, when no enteral feeding had been given,
so prenatal factors may have played a part. Some years ago, our
feeding policy for VLBW was changed to one of delayed enteral
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feeding.1 All VLBW infants received intravenous feeding only up to
7 days of age. Thereafter enteral feeding with a preterm formula
(’Nenatal’) was introduced with supplements of intravenous
feeding up to 150 ml/kg daily:
Amount
Day Enteral feeding Dilution (ml/kg per day)
8 Nenatal: glucose 5% 1:1 20
9 40
10 60
11 Nenatal: glucose 5% 3:1 60
12 80
13 100
14 Nenatal Undiluted 100
15 120
16 140
17 150
Before the start of enteral food intake, venous and low position
arterial umbilical lines were removed, and catheters were placed in
peripheral arteries and veins. With this regimen the incidence of
NEC in our VLBW population has been low for many years. We
agree with Lucas and Cole that breast milk may prevent NEC but
would not wish to stress the mothers of these sometimes very ill
babies further by forcing them to supply breast milk. Our results
show that the incidence of neonatal NEC can be low when preterm
formula is used. Whenever breast milk is not available we
recommend delayed introduction of diluted enteral feeding in
VLBW infants to prevent NEC.
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Captopril-induced IgA deficiency
SIR,&mdash;IgA deficiency is the most common form of primary
immunodeficiency, with a prevalence of 1 in 600 in a normal
population. The deficiency is often associated with sinopuhnonary
or gastrointestinal infections. Drugs, including penicillamine,1-3
phenytoin, sulphasalazine, gold salts, and diclofenac have been
shown to induce reversible or permanent IgA deficiency. Since the
aetiology of IgA deficiency is unknown, the study of drug-induced
cases is of considerable interest since it may throw light on the
molecular basis of the disorder.
Penicillamine contains a highly reactive sulphydryl group, which
has been implicated in the pathogenesis of drug-induced IgA
deficiency. 4 Captopril also has a sulphydryl group and it has been
successful in patients with rheumatoid arthritis. Captopril has been
TIME COURSE OF CAPTOPRIL-INDUCED IgA DEFICIENCY
Captopril treatment began on March 11, 1986. and was stopped at transplant on
May 5, 1988. Treatment with propanolol, frusemide, and prednisolone was
continued after transplant.
suspected but not proved to be associated with immunoglobulm
deficiency.6 We report a case strongly associating captopril with IgA
deficiency.
A 10-year-old girl with hypertension due to glomerulonephritis
was on long-term propranolol, frusemide, and prednisolone. In
March, 1986, captopril was added (6-25 mg daily, increasing to
18-75 mg in June, 1986). Serum IgA levels fell after half a year of this
treatment and were not detectable within a year (table). Levels of
IgG subclasses remained normal throughout (not shown). In May,
1988, the patient received a kidney graft and captopril was
discontinued. The serum IgA slowly rose to normal (table).
Captopril interacts with the immune system by inducing a
hypersensitivity response or by disruption of immune regulation
including the formation of immune complexes7 and
autoantibodies.8 This dysregulation seems also to affect IgA-
producing cells selectively, resulting, in rare cases, in the induction
of IgA deficiency. The chemical similarity between the two drugs
and the observation that both induce a similar pattern of
immunological disorder (systemic lupus, pemphigus, and IgA
deficiency) make it likely that the mechanism responsible for
penicillamine-induced side-effects is also responsible for the
adverse events induced by captopril.
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Thalidomide hypersensitivity in AIDS
SIR,&mdash;Treatment of severe aphthous oropharyngeal ulceration
with thalidomide has been described in patients with symptomatic
HIV infection by several groups.1,2 We have also seen rapid
alleviation of symptoms with this drug. However, we now report
that some patients have a hypersensitivity reaction that requires
discontinuation of therapy. We are not aware that this has been
reported before.
8 male patients with Centers for Disease Control stage IV HIV
infection presented with severe oropharyngeal aphthous ulceration.
In 7 patients, one or two large ulcers had developed in the tonsillar
region of the oropharynx (n = 5), alveolar ridge (n = 1), and base of
tongue (n = 1) causing severe pain and/or dysphagia over a period of
between one and twelve weeks. The eighth patient had had
recurrent multiple small oral aphthae over fifteen months but then
presented with a six-week history of persistent ulceration resistant
to topical treatment. Herpes simplex virus cultures were negative in
all patients and histological examination in 3 showed non-specific
inflammation and ulceration with no evidence of cytomegalovirus
inclusion bodies or malignant disease.
Previous therapies in 7 patients had failed. Thalidomide
(200 mg/day in 7 patients and 100 mg/day in 1) was begun and led to
rapid relief of pain with partial or complete healing in 7. In 1 patient
the dose was halved (100 mg) after three days because of drowsiness.
In a further 3 patients thalidomide was stopped early (six to twelve
days) because of a widespread erythematous macular rash.
Rechallenge was undertaken in 2 of these 3 patients because of
recurrence of pain and ulceration. Hypersensitivity reactions (fever,
